-
Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions
•
Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB 200 million ($29.8 million) in a Series B+ financing round led by Haier Capital. The round included participation from Xingtuo Capital and existing investors Innovation Works and Eastern Bell Capital. Proceeds will fuel market expansion,…
-
NMPA Issues New Vaccine Manufacturing and Distribution Rules
•
China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,” effective immediately. The finalized document includes amendments to a draft proposal from March, addressing pharmacovigilance, personnel requirements, and post-marketing management. Key Changes Overseas MAHs Supervision and Management Export and Import Rules
-
VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US
•
China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study of its dual-targeting drug VVN539 for open-angle glaucoma in the US. The trial marks progress in the company’s pipeline targeting ophthalmic disorders. Study DetailsThe randomized, double-blind, vehicle-controlled Phase II study will assess VVN539’s safety and…
-
Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact
•
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with Beijing Mabworks Biotech Co., Ltd to collaborate in biomedical technology services and new drug development. The partnership will cover drug discovery, process R&D, production, quality control, and clinical research through joint development, commissioned R&D, technical…
-
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
•
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a unit of US major Johnson & Johnson, to collaborate on the development of antibody drug conjugates (ADCs). The partnership will leverage DAC Bio’s proprietary ADC platform and Janssen’s antibody expertise for up to five targets.…
-
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…
-
Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
•
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of money in an angel financing round. The sole contributor to the round was ASB Ventures. The proceeds will be used to promote early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening, and…
-
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
•
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it is scaling back the US development of the programmed death-1 (PD-1) inhibitor tislelizumab. The firm no longer plans to file a New Drug Application (NDA) in the US for nasopharyngeal carcinoma (NPC) and has ended…
